Nov 21 2025
Future Neurology “Experiences of people with narcolepsy who switched from sodium oxybate to low-sodium oxybate: a plain language summary”

Aatif M. Husain, Phyllis C. Zee, Eileen B. Leary, Douglas S. Fuller, Shawn Candler, Marisa Whalen, Monica Gow & Charles J. Bae

“This plain language summary describes the experiences of people with narcolepsy who participated in the TENOR study. Narcolepsy is a rare condition that causes people to feel extremely sleepy during the day and can also cause unexpected muscle weakness (known as cataplexy). In the TENOR study, participants switched from a medication called sodium oxybate (SXB, also known as Xyrem®) to one called low-sodium oxybate (LXB, also known as Xywav®). LXB contains the same active drug as SXB, but with 92% less sodium than SXB. High sodium intake can raise the risk of cardiovascular problems, like high blood pressure and heart disease. The TENOR study looked at participants for 21 weeks after switching from SXB to LXB to understand how the medication change affected their narcolepsy symptoms, side effects, and overall experience.”

Check out the full summary here.